Acadian Asset Management
AIMT

Acadian Asset Management’s Aimmune Therapeutics AIMT Stock Holding History

Acadian Asset Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-36,330
Closed -$743K – 1861
2016
Q4 		$743K Buy
+36,330
New +$743K ﹤0.01% 777

Other funds holding AIMT

FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
TG
TLP Group Evanston, Illinois $6.61M AUM 12.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Acadian Asset Management's AIMT Position: Q1 2017 in Review

Acadian Asset Management sold out of Aimmune Therapeutics (AIMT) in Q1 2017, closing a stake of 36,330 shares — an estimated $743K sold.

Acadian Asset Management first reported a position in AIMT in Q4 2016 and held it in 1 quarter. The position peaked at $743K in Q4 2016. 90 funds tracked by Wall St. Rank hold AIMT as of Q1 2017.

  • Acadian Asset Management reported no remaining Aimmune Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Acadian Asset Management sold 36,330 Aimmune Therapeutics shares in Q1 2017, an estimated $743K.
  • Acadian Asset Management first reported a position in Aimmune Therapeutics in Q4 2016 and held it in 1 quarter.
  • Acadian Asset Management's Aimmune Therapeutics position peaked at $743K in Q4 2016.
  • 90 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q1 2017.

Based on Acadian Asset Management's 13F filing for Q1 2017, filed 25 Apr 2017.